TransMedics Group (NASDAQ:TMDX) Stock Price Down 3.8% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) was down 3.8% during mid-day trading on Thursday . The stock traded as low as $61.37 and last traded at $61.50. Approximately 93,896 shares changed hands during trading, a decline of 91% from the average daily volume of 1,048,580 shares. The stock had previously closed at $63.90.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TMDX shares. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Baird R W raised TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of 66.97 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a fifty day moving average of $84.31 and a two-hundred day moving average of $127.28.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the company earned ($0.12) EPS. The firm’s revenue was up 63.7% compared to the same quarter last year. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,180,642.53. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 19,417 shares of company stock worth $2,240,738. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James & Associates grew its position in shares of TransMedics Group by 152.4% during the 2nd quarter. Raymond James & Associates now owns 23,444 shares of the company’s stock valued at $3,531,000 after acquiring an additional 14,156 shares during the period. HB Wealth Management LLC purchased a new position in TransMedics Group during the 2nd quarter valued at about $318,000. Principal Financial Group Inc. raised its position in TransMedics Group by 603.9% in the 2nd quarter. Principal Financial Group Inc. now owns 56,172 shares of the company’s stock worth $8,461,000 after purchasing an additional 48,192 shares during the period. Signaturefd LLC lifted its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in TransMedics Group during the second quarter valued at about $47,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.